Skip to main content
Preview

Research from Friday’s close · next update overnight after Monday’s close

Radar
HBAN

HBAN Research brief

Huntington Bancshares

Adjusted close as of 2026-10-30
$15.78(−1.19%)

Sagehood’s view on HBAN

Huntington Bancshares · Research 2026-10-30 · Accepted

Research score

48Neutral50 is balancedScore change +3 since 2026-10-29, from 45 to 48; view unchanged at Neutral. Compare the two recordsConfidence 50 · It is not a calibrated probability of investment success.Confidence across the 100 names in this research run: 45 to 70, median 55.
How to read this score

Dated research brief

WhyHuntington's neutral read is driven by revenue growth that share issuance dilutes, since revenue rose 30.6% while the share count grew 28.3%. The unresolved risk is a 90-day slope of −39.8% with price 4.0% below 200-day average and a death cross 20 days old.
What argues against this viewThe strongest case against the neutral stance is that the balance sheet may be understated.
Break conditionFrom the financial specialist: A later reading showing the one-year share change at or below the 1% dilution level used in the equity-and-dilution test would break the dilution concern.Tests that specialist’s reading, not this page’s whole Neutral view.

Sagehood does not check this condition automatically. See research limitations below.

Valuation range

Close vs. model fair value · exit earnings multiple

Bear
$6.80
Base
$8.00
Bull
$13.10

Base case −49% vs. the 2026-10-30 close, on fundamentals to 2026-09-30. Peer-implied median $17.09 from 3 peer-median multiples. Estimates from this research’s valuation model, not a price target.

The market price implies more growth or higher margins than this model assumes, so its base case sits far below the close. The valuation specialist weighs that gap; it is not a forecast that the price will fall.

Against peers

Financials
MultipleHBANGroup medianPercentile
P/E (TTM)12.93×12.35×67th
P/S2.89×3.13×20th
P/B0.93×1.40×0th
Score details & research limitations9 unavailable fields
Conditions Sagehood can check on its ownNot available in this run. A written break condition is not an automated check; this run does not provide a source-linked rule Sagehood can verify on its own.

Where the break condition comes from: Sagehood research took this condition from the financial specialist. It tests that specialist’s own reading, so it does not say everything that would change this page’s Neutral view.

How to read this research

The score expresses the published research view. 50 is balanced.

Bullish, Neutral or Bearish beside the score is the direction of that view, set by the research from the score: 65 and above is Bullish, 45 to 64 Neutral, 44 and below Bearish.

Confidence is how well the evidence supports this view, not which way it points: Sagehood research is asked to keep it no higher than its most confident specialist, and lower when the specialists disagree or much of the evidence is weak. It is not a calibrated probability of investment success.

Source verification checks the identity and origin of evidence. It does not prove that a claim is correct or that an investment will succeed.

Valuation estimates depend on their inputs and assumptions. They are not guaranteed future prices.

Retrospective research looks back at an earlier period. It is not a verified record of a decision made then using only information available then.

Unavailable is not zero. Read the adjacent reason: information may be missing, unverified or deliberately withheld.

How Sagehood works

The session this view is fixed to

Close$15.78 on 2026-10-30, as the research recorded it
Change on the day−1.19%
First eligible market session2026-11-02

Recorded score context

Specialist source coverage8 of 10 specialists have a verified source on this run. 2 do not.
Score reconciliationThe 8 specialist contributions shown add up to the weighted starting point this score was built from.
Change since the last accepted run45 on 2026-10-29 → 48 on 2026-10-30 (+3 points). This is simple arithmetic between the two published scores, not an explanation of the change.
The run this is compared withResearch of 2026-10-29

Not in this run: Run-specific score definition, Confidence band, Horizon, Why the score changed, Today's unexplained move and Blockers.

What this was built from

Filing cited in the evidenceNot recorded on this card. The newest filing on record is under Key financials, and recent filings are listed under SEC filings.
Peer set10 names in Financials: BAC, C, COIN, HOOD, KEY, PYPL, RF, SCHW, TFC, WFC. How they were chosen is under “Valuation & peers”. The valuation range shows the peer-implied median from 3 peer-median multiples.

Not in this run: Company profile date and Standing disclosure.

Not available in this run

9 fields are unavailable. Each is identified with its reason above; missing information is not zero or a negative research signal.

Price context

· adjusted close $15.78

−11.0% from 2026-06-25

Recent price-basis check: 2026-10-02 to 2026-10-30 (20 sessions). Economic comparability outside this window remains unchecked.

HBAN adjusted close
Adjusted price · USD · viewing 2026-06-25 to 2026-10-30

Selected 2026-10-30. HBAN adjusted close. Continuous series. $15.78 US dollars.

90 daily adjusted-price observations through 2026-10-30, ending at the 2026-10-30 research date. The final point is a dated final close. Shown for context, not point-in-time research evidence: the research used the prices recorded with it.

Use the arrow keys on the chart to step through observations.

Published score history

2026-07-23 to 2026-10-30 · 37 publications

Each point is a verified published score. The line breaks where the research method changed (4 methods, numbered in the order they were first used), so scores are not joined across methods. Hollow points were published after their decision window (retrospective).

Every published score and confidence
Research dateScoreViewConfidenceMethod
2026-10-3048Neutral50Method 4
2026-10-2945Neutral50Method 4
2026-10-2843Bearish45Method 4
2026-10-2744Bearish50Method 4
2026-10-2650Neutral45Method 4
2026-10-2350Neutral50Method 4
2026-10-2248Neutral45Method 4
2026-10-2147Neutral45Method 4
2026-10-1642Bearish45Method 4
2026-10-0941Bearish40Method 4
2026-10-0742Bearish44Method 4
2026-10-0244Bearish55Method 4
2026-10-0142Bearish50Method 4
2026-09-3043Bearish48Method 4
2026-09-2943Bearish48Method 4
2026-09-2844Bearish48Method 4
2026-09-2542Bearish50Method 4
2026-09-24 · retrospective42Bearish50Method 4
2026-09-2343Bearish50Method 4
2026-09-1846Neutral65Method 4
2026-09-16 · retrospective41Bearish50Method 4
2026-09-09 · retrospective45Neutral48Method 4
2026-09-0450Neutral65Method 4
2026-09-01 · retrospective46Neutral60Method 4
2026-08-31 · retrospective52Neutral61Method 3
2026-08-2852Neutral61Method 3
2026-08-26 · retrospective53Neutral61Method 3
2026-08-24 · retrospective53Neutral61Method 3
2026-08-20 · retrospective50Neutral61Method 3
2026-08-19 · retrospective52Neutral61Method 3
2026-08-1456Neutral61Method 2
2026-08-1356Neutral61Method 1
2026-08-0752Neutral61Method 1
2026-08-0651Neutral61Method 1
2026-08-0452Neutral61Method 1
2026-07-3148Neutral66Method 1
2026-07-2348Neutral58Method 1

Specialists

8 of 10 published specialist analyses are available.

Each specialist’s view is shown as the published research recorded it; supporting detail appears only when it was recorded with that same view.

2 unavailable

HBAN research

Financial specialist

Showing Financial specialist result.

Financial specialist

Evaluated for this session

Neutral

Huntington's revenue is growing fast, with trailing-twelve-month revenue of $10,375 million up 30.6% versus the 5.4% sector revenue-growth median, but a 28.3% one-year share-count increase dilutes that growth and return on equity is 9.1%.

Full analyst note

What the specialist sees

Evidence: trailing-twelve-month revenue of $10,375 million grew 30.6% against the 5.4% sector revenue-growth median, but the 9.1% return on equity and a 28.3% one-year share-count increase point to dilution.

Why it matters now

Fast revenue growth is being funded partly by issuing shares, so per-share economics lag the top line; the 24.0% trailing-twelve-month net margin is the offsetting support.

What could change the view

Countercase: The 28.3% share-count increase and 9.1% return on equity could be distorted by an acquisition whose earnings contribution is not yet visible, which the input does not establish. Falsifier: A later reading showing the one-year share change at or below the 1% dilution level used in the equity-and-dilution test would break the dilution concern.

Specialist score details
Specialist score
50
Evidence confidence
80
Base weight for this role
0.13
Base weight × confidence
10.40
Weight in the score (the chip's weight)
0.22
Weighted contribution
10.80
Business driver
Trailing-twelve-month revenue of $10,375 million grew 30.6% against the 5.4% sector revenue-growth median, but the 9.1% return on equity and a 28.3% one-year share-count increase point to dilution.
Mechanism
Fast revenue growth is being funded partly by issuing shares, so per-share economics lag the top line; the 24.0% trailing-twelve-month net margin is the offsetting support.
Countercase
The 28.3% share-count increase and 9.1% return on equity could be distorted by an acquisition whose earnings contribution is not yet visible, which the input does not establish.
Contributions & coverage details

Specialist contributions

Each specialist’s recorded numbers, in the usual specialist order, as recorded: nothing is re-ranked or recalculated. Weights and contributions show two decimals; hover for the exact value.

Financial specialist

Neutral

Score
50
Evidence confidence
80
Weight in the score
0.22
Weighted contribution
10.80

Risk specialist

Neutral

Score
52
Evidence confidence
55
Weight in the score
0.09
Weighted contribution
4.75

Sector specialist

Bearish

Score
40
Evidence confidence
62
Weight in the score
0.13
Weighted contribution
5.15

SEC filings specialist

Neutral

Score
50
Evidence confidence
55
Weight in the score
0.03
Weighted contribution
1.71

News specialist

Neutral

Score
50
Evidence confidence
50
Weight in the score
0.11
Weighted contribution
5.71

Price-trend specialist

Neutral

Score
48
Evidence confidence
50
Weight in the score
0.21
Weighted contribution
9.97

Valuation specialist

Bearish

Score
40
Evidence confidence
35
Weight in the score
0.12
Weighted contribution
4.65

Economy specialist

Neutral

Score
54
Evidence confidence
55
Weight in the score
0.09
Weighted contribution
4.93

Published specialist analyses unavailable: Geopolitics specialist, Social-media specialist. No specialist result is inferred.

  • Geopolitics specialist: This specialist had no checked public source on this run, so no source-backed analysis is shown.
  • Social-media specialist: This specialist had no checked public source on this run, so no source-backed analysis is shown.

How this insight was formed

Each specialist view shown here is checked against the published research files. Sagehood research combined those views into the one Research Score above.

Evidence & method

Inspect the reasoning, source records and valuation behind this dated view.

Sagehood research reasoningSpecialist reasoning, selected statements and filing context
Accepted publication2026-10-30 researchNext eligible session 2026-11-02point-in-time

HBAN: Sagehood research reasoning

Accepted research score

48

Neutral50 is balanced
Lead specialist in the research decision:

Financial specialist

Neutral

Specialist score 50Evidence confidence 80
What the specialist sees

Trailing-twelve-month revenue of $10,375 million grew 30.6% against the 5.4% sector revenue-growth median, but the 9.1% return on equity and a 28.3% one-year share-count increase point to dilution.

Why it matters

Fast revenue growth is being funded partly by issuing shares, so per-share economics lag the top line; the 24.0% trailing-twelve-month net margin is the offsetting support.

What argues against it

The 28.3% share-count increase and 9.1% return on equity could be distorted by an acquisition whose earnings contribution is not yet visible, which the input does not establish.

This specialist’s break condition: A later reading showing the one-year share change at or below the 1% dilution level used in the equity-and-dilution test would break the dilution concern.

How the score was formed

The specialists’ weighted starting point was 47.68. Sagehood research’s adjustment was +0.32. 45 on 2026-10-29 → 48 on 2026-10-30 (+3 points). This is simple arithmetic between the two published scores, not an explanation of the change.

Evidence Sagehood research weighed

These selected claims are evidence Sagehood research weighed, not a reconstruction of the numeric adjustment.

Claims as this research published them. Sagehood confirms each claim and its support were published together with this research. That is not an independent check, and it does not prove the claim is accurate or predict future performance.

  1. Financial specialist

    Same statement as under “What the specialist sees” above.

  2. Price-trend specialist

    HBAN closed at 15.78, up 2.94% over 20 days but down 8.2% over 60 days, with rsi14D at 53.3 and rsi14W at 44.7. The 90-day channel slope is −39.8% with trend-channel position 1.58 standard deviations, and the death cross is 20 days old.

  3. Valuation specialist

    The EPS-model base case pairs −2.7% EPS growth with a 12.3 exit P/E for an $8.0 fair value, 49% below the $15.78 close, while the comps median of $17.09 implies 8.3% upside and trailing-twelve-month EPS is $1.22.

Sagehood research decision

The investment case, main risk and break condition are the ones shown under Sagehood’s view at the top of this page.

Recorded break condition
Break condition as kept in the decision trail

A later reading showing the one-year share change at or below the 1% dilution level used in the equity-and-dilution test would break the dilution concern.

Evidence & sourcesClaim-support availability, filing-context links and research method

HBAN: This run has no checked links from its claims to their evidence. The specialists’ writing is shown as recorded, and no missing evidence is filled in.

Research evidence at a glance

Accepted specialist evidence · no score adjustment

Key figures

Fundamentals

Trailing-twelve-month revenue of $10,375 million grew 30.6% against the 5.4% sector revenue-growth median, but the 9.1% return on equity and a 28.3% one-year share-count increase point to dilution.

Valuation model

The EPS-model base case pairs −2.7% EPS growth with a 12.3 exit P/E for an $8.0 fair value, 49% below the $15.78 close, while the comps median of $17.09 implies 8.3% upside and trailing-twelve-month EPS is $1.22.

Potential upside

  • Huntington's revenue is growing fast, with trailing-twelve-month revenue of $10,375 million up 30.6% versus the 5.4% sector revenue-growth median, but a 28.3% one-year share-count increase dilutes that growth and return on equity is 9.1%.

Potential downside

  • EPS-model base fair value of $8.0 is 49% below the $15.78 close, and the comps median of $17.09 implies 8.3% upside, so the methods disagree. Revenue CAGR of 4.0% over three years and a 0.93 price-to-book anchor the read.

Questions to watch

  • A later reading showing the one-year share change at or below the 1% dilution level used in the equity-and-dilution test would break the dilution concern.

  • A later filing showing EPS growth at or above 2% would break the below-close read, because the base case's $8.0 fair value rests on the −2.7% growth row.

Accepted research

Research dated 2026-10-30.

How this research was made

This research is AI-generated and is not investment advice.

Research date
2026-10-30
Valuation & peersInput limits notedFair-value cells, peer multiples and the inputs behind the range

Valuation the research computed

Against the 2026-10-30 close of $15.78 (recorded)

Fundamentals reference date: 2026-09-30.

Fair value by exit earnings multiple, at the cells this run nominated.

Bear
$6.80−57% vs close
Base
$8.00−49% vs close
Bull
$13.10−17% vs close

Implied by the median of 3 peer-median multiples: $17.09 (+8.3% vs close)

Peers: the 10 Liquid 100 names in Financials that this run priced. Companies outside the Liquid 100 are not in the set.

The names: BAC, C, COIN, HOOD, KEY, PYPL, RF, SCHW, TFC, WFC.

Multiples against the peer group

Financials · 10 companies in the group

  • Price to earnings (trailing twelve months)12.93×

    Peer median 12.35× · middle half 11.76× to 16.04× · 67th percentile of the group

  • Price to sales2.89×

    Peer median 3.13× · middle half 2.97× to 5.26× · 20th percentile of the group

  • Price to book0.93×

    Peer median 1.40× · middle half 1.19× to 2.72× · 0th percentile of the group

  • Free cash flow yield9.74%

    Peer median 6.09% · middle half −3.98% to 8.25% · 75th percentile of the group

    Free cash flow is not in the financial analysis for financial and real-estate names, and no fair-value figure in this research uses it, including the peer-implied figure.

This run declares Enterprise value to EBITDA and computes no value for it, for this company or for its peer group.

Evidence limits: 7 valuation inputs required conservative handling: another valuation input required conservative handling; no full-year gross-profit line was filed; no full-year operating income was filed; depreciation and amortization were available but not used because this version does not compute an EV/EBITDA multiple.

Includes the currently displayed specialist or comparison, not every specialist. Dates and limitations remain attached.

Sagehood research is for general information. It is not individualized investment advice or a recommendation to buy or sell any security.

Huntington Bancshares (HBAN) research | Sagehood